The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW to Propose “Special Rule” for Indication Change Re-Pricing
November 21, 2019
-
BUSINESS Sumitomo Dainippon to Solely Promote Novartis Diabetes Meds from January
November 20, 2019
-
BUSINESS Mitsubishi Chemical to Fully Own Mitsubishi Tanabe to Solidify Healthcare Platform
November 19, 2019
-
ORGANIZATION RIKEN Develops Supercomputer for Molecular Dynamics Simulation, Will Be Made Available to Drug Makers for Drug Discovery Use
November 19, 2019
-
COMMENTARY Finance Officials, Payers Grow Jittery as Xolair’s Pollen Allergy Nod Looms
November 18, 2019
-
REGULATORY Will Japan Reinstate Sakigake Status for Aducanumab? Many See It Unlikely
November 15, 2019
-
BUSINESS Big 4 Japan Wholesalers Eke Out 1% Operating Margins: Jiho Tally
November 14, 2019
-
REGULATORY Keytruda to Get 17.5% Price Cut in February
November 13, 2019
-
REGULATORY Keytruda Faces Price Slash on Better-than-Expected Sales
November 12, 2019
-
REGULATORY Japan to Use September 2019 Market Price Data for 2020 Revisions, April 2018 NHI Prices as Baseline
November 11, 2019
-
REGULATORY Opposition Party Set to Compile HPV Vaccine Proposal by Year-End
November 8, 2019
-
BUSINESS As Trintellix Debut Nears, Lundbeck Japan Morphing into Full-Fledged Commercial Company
November 7, 2019
-
BUSINESS 8 Japan Majors Log Combined Sales Rise in 1st Half on Shire Buy, Solid Earnings at Home
November 6, 2019
-
REGULATORY MOF Frets Financial Impact of Pricey Meds for Big Patient Populations, Cites Xolair’s Use in Pollen Allergy
November 5, 2019
-
BUSINESS Sumitomo, Roivant Ink Definitive Alliance Deal; Ex-Genentech Exec to Wield Baton
November 1, 2019
-
BUSINESS Eisai CEO Says Aducanumab Resurrection Was a Surprise, Touts Totality of Data as He Relays New Findings
October 31, 2019
-
BUSINESS Nesp Biosame Soon to Leapfrog Originator as 5.6 Billion Yen Logged in Just 2 Months
October 30, 2019
-
REGULATORY CEFP Members Prod Govt to Set Value-Based Target for Generic Promotion, but MHLW Wary
October 29, 2019
-
BUSINESS AbbVie Embarking on Work Style Reform for Sales Reps, Lets Staffers Pick Locations
October 28, 2019
-
BUSINESS Chugai Notches Up Record Earnings in January-September on Hemlibra, Mainstays
October 25, 2019
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…